CN100475812C - 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶 - Google Patents

作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶 Download PDF

Info

Publication number
CN100475812C
CN100475812C CNB038220113A CN03822011A CN100475812C CN 100475812 C CN100475812 C CN 100475812C CN B038220113 A CNB038220113 A CN B038220113A CN 03822011 A CN03822011 A CN 03822011A CN 100475812 C CN100475812 C CN 100475812C
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038220113A
Other languages
English (en)
Chinese (zh)
Other versions
CN1681816A (zh
Inventor
M·P·德怀尔
T·J·古兹
K·帕鲁奇
R·J·多尔
K·M·基尔蒂卡
V·M·吉里亚瓦拉布汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1681816A publication Critical patent/CN1681816A/zh
Application granted granted Critical
Publication of CN100475812C publication Critical patent/CN100475812C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038220113A 2002-09-19 2003-09-17 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶 Expired - Fee Related CN100475812C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41213802P 2002-09-19 2002-09-19
US60/412,138 2002-09-19

Publications (2)

Publication Number Publication Date
CN1681816A CN1681816A (zh) 2005-10-12
CN100475812C true CN100475812C (zh) 2009-04-08

Family

ID=32030811

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038220113A Expired - Fee Related CN100475812C (zh) 2002-09-19 2003-09-17 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶

Country Status (18)

Country Link
US (1) US7151104B2 (enExample)
EP (1) EP1539750B1 (enExample)
JP (1) JP4845380B2 (enExample)
KR (1) KR20050072090A (enExample)
CN (1) CN100475812C (enExample)
AR (1) AR041292A1 (enExample)
AT (1) ATE382048T1 (enExample)
AU (1) AU2003270846B2 (enExample)
CA (1) CA2499593C (enExample)
DE (1) DE60318321T2 (enExample)
ES (1) ES2297203T3 (enExample)
IL (1) IL167432A (enExample)
MX (1) MXPA05003059A (enExample)
MY (1) MY136840A (enExample)
NZ (1) NZ538595A (enExample)
TW (1) TWI283243B (enExample)
WO (1) WO2004026872A1 (enExample)
ZA (1) ZA200502271B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
JPWO2006090930A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規併用
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
JPWO2006109867A1 (ja) * 2005-04-07 2008-11-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリジン誘導体またはその医学上許容される塩
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
WO2007032936A2 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
CN101621931A (zh) * 2006-11-27 2010-01-06 H.隆德贝克有限公司 杂芳基酰胺衍生物
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP6861166B2 (ja) * 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
EA038701B1 (ru) * 2016-09-07 2021-10-07 Хайхэ Биофарма Ко., Лтд. Пиридо пятичленное ароматическое циклическое соединение, способ его получения и применение

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202896C (zh) * 2002-02-07 2005-05-25 北京燕化高新技术股份有限公司 空气分离时纯化空气的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066147C (zh) 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
CA2314355A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
JP4039856B2 (ja) * 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
US20040048849A1 (en) 2000-12-20 2004-03-11 Gregoire Prevost Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
BR0207762A (pt) * 2001-03-08 2004-06-01 Astrazeneca Ab Uso de um composto ou um sal farmaceuticamente aceitável do mesmo, combinação, formulação farmacêutica, kit, método para a prevenção da úlcera gástrica induzida por medicamento, e, composição farmacêutica oral

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202896C (zh) * 2002-02-07 2005-05-25 北京燕化高新技术股份有限公司 空气分离时纯化空气的方法

Also Published As

Publication number Publication date
ZA200502271B (en) 2005-09-19
TW200409775A (en) 2004-06-16
AR041292A1 (es) 2005-05-11
CA2499593A1 (en) 2004-04-01
NZ538595A (en) 2006-04-28
TWI283243B (en) 2007-07-01
WO2004026872A1 (en) 2004-04-01
AU2003270846A1 (en) 2004-04-08
IL167432A (en) 2010-05-17
HK1071758A1 (en) 2005-07-29
ATE382048T1 (de) 2008-01-15
CA2499593C (en) 2011-08-16
US7151104B2 (en) 2006-12-19
MY136840A (en) 2008-11-28
EP1539750B1 (en) 2007-12-26
JP2006503060A (ja) 2006-01-26
AU2003270846B2 (en) 2006-11-23
DE60318321T2 (de) 2008-12-11
MXPA05003059A (es) 2005-05-27
DE60318321D1 (en) 2008-02-07
KR20050072090A (ko) 2005-07-08
ES2297203T3 (es) 2008-05-01
CN1681816A (zh) 2005-10-12
US20040097516A1 (en) 2004-05-20
EP1539750A1 (en) 2005-06-15
JP4845380B2 (ja) 2011-12-28

Similar Documents

Publication Publication Date Title
JP4845379B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
JP4790265B2 (ja) サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP4700344B2 (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
CN100475812C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶
US20100137326A1 (en) NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS
JP2006503838A (ja) サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
JP2006502184A5 (enExample)
JP2006507253A (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
JP2011074088A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
HK1071758B (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
HK1112229B (en) Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines compounds as cyclin dependent kinase inhi

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090408

Termination date: 20120917